Welcome to our dedicated page for Jazz Pharmaceuticals Plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jazz Pharmaceuticals plc (Nasdaq: JAZZ) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, alongside AI-assisted summaries to help interpret complex documents. Jazz, an Ireland-incorporated global biopharma company, files current and periodic reports as an issuer with ordinary shares listed on The Nasdaq Stock Market LLC under the symbol JAZZ.
Investors and researchers can review Form 8-K filings that report material events, including clinical trial milestones for products such as Ziihera (zanidatamab-hrii), financial results for specific quarters, executive and board changes, and legal settlements related to its sleep disorder and epilepsy franchises. These current reports often reference accompanying press releases that provide additional narrative detail on oncology and neuroscience developments.
Through this page, users can also locate references to quarterly and annual reports (Forms 10-Q and 10-K when available), which typically contain broader discussions of Jazz’s business, risk factors, pipeline, marketed medicines and financial condition. In addition, proxy materials and shareholder meeting results, such as votes on director elections and auditor appointments, are accessible for those tracking governance matters.
Stock Titan’s AI tools are designed to highlight key points from lengthy filings, helping users quickly identify sections related to oncology programs, neuroscience assets, royalty and settlement agreements, or capital markets activity. Where applicable, investors can also review insider-related filings such as Forms 3, 4 and 5 to monitor transactions in JAZZ ordinary shares by directors and officers, as reported to the SEC.
By combining real-time EDGAR updates with AI-generated overviews, this page offers a practical way to follow how Jazz Pharmaceuticals documents its clinical progress, corporate actions and financial reporting obligations in the U.S. regulatory framework.
Heather McSharry, a director of Jazz Pharmaceuticals (JAZZ), received 3,507 restricted stock units on 08/07/2025 under the company's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each unit is a contingent right to one ordinary share and, subject to continued service and conditions, will vest in full on 07/24/2026.
On 08/08/2025 she sold 1,959 ordinary shares at $111.2497 per share to satisfy tax obligations arising from prior RSU vesting, leaving her with 20,449 ordinary shares beneficially owned (direct) following the reported transactions.
Anne O'Riordan, a director of Jazz Pharmaceuticals plc (JAZZ), filed a Form 4 reporting a grant of restricted stock units and a sale to cover taxes. On 08/07/2025 she was granted 3,507 restricted stock units under the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan; each unit represents a contingent right to one ordinary share and these units vest in full on July 24, 2026 subject to continuous service and additional conditions. On 08/08/2025 she sold 1,805 shares at $111.2494 per share to satisfy tax obligations arising from the vesting of previously granted RSUs. The filing shows beneficial ownership of 18,305 shares following the grant and 16,500 shares following the sale. The Form 4 was signed by an attorney-in-fact on 08/11/2025.
Norbert G. Riedel, a director of Jazz Pharmaceuticals (JAZZ), reported changes in his beneficial ownership on Form 4. On 08/07/2025 he was granted 3,507 restricted stock units under the issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan; each unit represents a contingent right to one ordinary share and the units vest in full on July 24, 2026. On 08/08/2025 he sold 1,805 ordinary shares at $111.2498 per share to satisfy tax obligations arising from prior RSU vesting, with 7,024 shares reported as beneficially owned directly after the sale. The filing also discloses 10,630 shares beneficially owned indirectly by the Norbert G. Riedel 2023 Trust. The Form 4 was signed by attorney Adam Guttmann on 08/11/2025.
Mark D. Smith, a director of Jazz Pharmaceuticals plc (JAZZ), reported two related equity transactions. On 08/07/2025 he was recorded as acquiring 3,507 restricted stock units (RSUs) under the companys 2007 Non-Employee Directors Stock Award Plan; each unit represents a right to receive one ordinary share and the RSUs are scheduled to vest in full on July 24, 2026 subject to service and plan conditions. The filing shows these units recorded at a $0.0 acquisition price for reporting purposes.
On 08/08/2025 the reporting person disposed of 1,805 ordinary shares at a price of $111.2502 per share to satisfy tax obligations arising from the vesting of previously granted RSUs. After the transactions the filing lists 10,837 shares beneficially owned by the reporting person.
Rick E Winningham, a director of Jazz Pharmaceuticals (JAZZ), reported a grant of 3,507 restricted stock units on 08/07/2025. Each restricted stock unit represents a contingent right to receive one ordinary share and, subject to continued service and conditions, the units are scheduled to vest in full on July 24, 2026. The grant is under the issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan and is reported with an acquisition price of $0.00.
The filing also discloses a sale on 08/08/2025 of 1,805 shares at $111.2524 described as shares sold to satisfy tax obligations arising from prior RSU vesting. Reported beneficial ownership moved from 16,198 shares after the grant to 14,393 shares after the sale.
Seamus Mulligan, a director of Jazz Pharmaceuticals (JAZZ), was granted 3,507 restricted stock units on 08/07/2025. Each unit represents a contingent right to one ordinary share and, subject to continuous service and plan conditions, the units will vest in full on July 24, 2026.
Following the reported transaction, the filing shows the reporting person beneficially owns 1,179,613 shares directly and 101,621 shares indirectly through Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family. The grant was made under the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan.
Renee D. Gala, President & CEO of Jazz Pharmaceuticals (JAZZ), reported a grant of 18,808 restricted stock units (RSUs) under the Issuer's 2011 Equity Incentive Plan with a vesting schedule measured from a September 2025 commencement date. Each RSU represents a contingent right to one ordinary share and vests in equal annual installments over four years, with one-quarter vesting on the first anniversary. The filing also discloses acquisition of 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 30, 2025. Following the reported transactions, Ms. Gala beneficially owns 107,869 ordinary shares.
Form 144 notice for Jazz Pharmaceuticals (JAZZ) reports a proposed sale of 3,731 common shares on NASDAQ with an aggregate market value of $417,872. The form lists total shares outstanding as 60,658,809 and an approximate sale date of 08/08/2025.
The shares were acquired on 08/07/2025 through restricted stock vesting from the issuer and the form records payment/compensation as of 08/07/2025. ETRADE FINANCIAL CORPORATION is named as the broker. The filer indicates no securities sold in the past three months and attests they are not aware of undisclosed material adverse information about the issuer.
The filing is a Form 144 reporting a proposed sale of 3,731 shares of common stock with an aggregate market value of $417,872. The securities are listed as outstanding in the amount of 60,658,809 shares and the proposed sale is identified for 08/08/2025 on NASDAQ.
The shares were acquired on 08/07/2025 as restricted stock vesting from the issuer and the consideration is listed as compensation. The form notes "Nothing to Report" for securities sold during the past three months. Several filer contact fields (including CIK and submission contact details) appear blank in the provided content.
Jazz Pharmaceuticals (JAZZ) submitted a Form 144 reporting a proposed sale of 3,731 shares of common stock through ETRADE Financial Corporation on 08/08/2025 with an aggregate market value of $417,872. The filing shows the shares were acquired on 08/07/2025 through restricted stock vesting and were granted as compensation. The form states there were no securities sold in the past three months by the selling person and includes the seller's certification that they are not aware of undisclosed material adverse information about the issuer. The shares represent a very small fraction of the 60,658,809 shares outstanding.
FAQ
What is the current stock price of Jazz Pharmaceuticals Plc (JAZZ)?
What is the market cap of Jazz Pharmaceuticals Plc (JAZZ)?
